Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Mark
Cara Therapeutics: Scratching At Multiple Indications In 2020 (NASDAQ:CARA) | Seeking Alpha
EX-99.2
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Articles with Cara Therapeutics, Inc. | page 5
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - ScienceDirect
Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
Cara Therapeutics: Developing Novel Peripheral Kappa Opioid Product Candidates
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
1Washington University, St. Louis, MO, USA; 2Trevi Therapeutics, New Haven, CT, USA; 3University of Miami, Miami, FL, USA Introd
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | NEJM
Pharmaceuticals | Free Full-Text | Therapeutic Potential of Kappa Opioid Agonists
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Difelikefalin: First Approval
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Experimental Kappa Opioid Appears Safe and Effective
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing? | Semantic Scholar
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
